TURLI GENEZLI SURUNKALI PANKREATIT RIVOJLANISHINING MOLEKULYAR-GENETIK JIHATLARI
##article.subject##:
surunkali pankreatit, molekulyar-genetik jihatlar##article.abstract##
Surunkali pankreatit (SP) oshqozon osti bezining progressiv yallig‘lanish kasalligi bo‘lib, uzoq muddatli kechishi va fibroz rivojlanishi bilan tavsiflanadi, bu esa a’zo funksiyasining buzilishiga olib kelishi mumkin. Tibbiyotdagi sezilarli yutuqlarga qaramay, surunkali pankreatitni tashxislash va davolash murakkab va ko‘p qirrali vazifa bo‘lib qolmoqda. Bu ko‘plab omillar bilan bog‘liq, masalan, etiologik omillarning xilma-xilligi, kasallikning kech tashxisi va universal davolash usullarining yo‘qligi. Surunkali pankreatitning patogenezini tushunishning eng muhim jihatlaridan biri molekulyar genetik yondashuvdir. Kasallikning rivojlanishida genetik moyillik asosiy rol o‘ynaydi va so‘nggi o‘n yilliklarda turli xil genezli SP rivojlanishiga hissa qo‘shishi mumkin bo‘lgan bir nechta genlar aniqlandi.
Библиографические ссылки
Etemad B, Whitcomb DC: Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology, 2001; 120: 682–707
Witt H: Chronic pancreatitis and cystic fibrosis. Gut, 2003; 52(Suppl.2): ii31–41
Comfort M, Steinberg A: Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology, 1952; 21: 54–63
Keim V, Bauer N, Teich N et al: Clinical characteristics of patients with hereditary pancreatitis and mutations in cationic trypsinogen. Am J Med, 2001; 111: 622–26
Moir CR, Konzen KM, Perrault J: Surgical therapy and long-term follow-up of childhood hereditary pancreatitis. J Pediatr Surg, 1992; 27: 282–86
Miller AR, Nagorney DM, Sarr MG: The surgical spectrum of hereditary pancreatitis in adults. Ann Surg, 1992; 215: 39–43
Lowenfels AB, Maisonneuve P, DiMagno EP et al: Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst, 1997; 89: 442–46
Ulrich CD: Pancreatic Cancer in Hereditary Pancreatitis: Consensus Guidelines for Prevention, Screening and Treatment. Pancreatology, 2001; 1: 416–22
Whitcomb DC, Gorry MC, Preston RA et al: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet, 1996; 14: 141–45
Gorry MC, Gabbaizedeh D, Furey W et al: Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology, 1997; 113: 1063–68
Witt H, Luck W, Becker M: A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology, 1999; 117: 7–10
Teich N, Bauer N, Mössner J, Keim V: Mutational screening of patients with nonalcoholic chronic pancreatitis: Identification of further trypsinogen variants. Am J Gastroenterol, 2002; 97: 341–46
Kukor Z, Mayerle J, Kruger B et al: Presence of cathepsin B in the human pancreatic secretory pathway and its role in trypsinogen activation during hereditary pancreatitis. Biol Chem, 2000; 277: 21389–96
Kukor Z, Toth M, Pal G, Sahin-Toth M: Human cationic trypsinogen. Arg(117) is the reactive site of an inhibitory surface loop that controls spontaneous zymogen activation. J Biol Chem, 2002; 277: 6111–17
Sahin-Toth M: Human cationic trypsinogen. Role of Asn-21 in zymogen activation and implications in hereditary pancreatitis. J Biol Chem, 2000; 275: 22750–55
Sahin-Toth M. The pathobiochemistry of hereditary pancreatitis: studies on recombinant human cationic trypsinogen. Pancreatology, 2001; 1: 461–65
Sahin-Toth M, Toth M: Gain-of-function mutations associated with hereditary pancreatitis enhance autoactivation of human cationic trypsinogen. Biochem Biophys Res Commun, 2000; 278: 286–89
Simon P, Weiss FU, Sahin-Toth M et al: Hereditary pancreatitis caused by a novel PRSS1 mutation (Arg-122->Cys) that alters autoactivation and autodegradation of cationic trypsinogen. J Biol Chem, 2002; 277: 5404–10
Szilagyi L, Kenesi E, Katona G et al: Comparative in vitro studies on native and recombinant human cationic trypsins. Cathepsin B is a possible pathological activator of trypsinogen in pancreatitis. J Biol Chem, 2001; 276: 24574–80
Teich N, Ockenga J, Hoffmeister A et al: Chronic pancreatitis associated with an activation peptide mutation that facilitates trypsin activation. Gastroenterology, 2000; 119: 461–65
JA Rizaev , I. R. Agababyan , YAIsmoilova ACTIVITIES OF CLINICS SPECIALIZING IN THE TREATMENT OF PATIENTS WITH CHRONIC HEART DISEASE IN THE WORLD (REFERENCES). Journal of Biomedicine and Practice. 2021, vol. 6, issue 6, pp. 184-191
Makhmonov L.S., Rizaev Zh.A., Gadaev A.G. HELICOBACTER PYLORI AND ITS IMPORTANCE IN THE DEVELOPMENT OF ANEMIA ASSOCIATED WITH IRON DEFICIENCY AND VITAMIN B12 // Problems of biology and medicine. - 2021. No. 5. Volume . 130. - S. 215-218.
Irgashev, K. N., & Rizaev, J. A. (2025). Optimization of clinical outcomes in the rehabilitation of patients with non-caries dental lesions manifesting as pathological abrasion. Medical Research Journal, 1(1), 146–151.
Shavkatovna, S. S., Makhammatkulovich, R. N., & Ugli, M. S. T. (2024). Aspects of sarcopenia syndrome in oncological practice: Diagnosis and treatment. The American Journal of Medical Sciences and Pharmaceutical Research, 6(2).
Shakhanova, S. S., & Rakhimov, N. M. (2025). The role of troponin and IL-6 in immunological assessment of sarcopenia in oncological patients. Central Asian Journal of Medical and Natural Science, 6(3), 1229–1233.
Rakhimov, N. M., & Shakhanova, S. Sh. (2025). Omega-3 supplementation in combination therapy for anorexia syndrome in metastatic breast cancer. American Journal of Medicine and Medical Sciences.
